Literature DB >> 22692571

Prognostic scoring system for stage IV colorectal cancer: is the AJCC sub-classification of stage IV colorectal cancer appropriate?

Hirotoshi Kobayashi1, Kenjiro Kotake, Kenichi Sugihara.   

Abstract

BACKGROUND: Stage IV colorectal cancer encompasses various clinical conditions. The aim of this study was to validate the utility of the recent AJCC stage IV colorectal cancer sub-classification, and to establish a prognostic scoring system using independent factors.
METHODS: We conducted a retrospective analysis using data from the multicenter registry. Factors affecting the curative resection and prognosis were analyzed in patients with stage IV colorectal cancer.
RESULTS: Of the 60,176 patients who received surgery for colorectal cancer, 9,624 (16.0 %) were classified as stage IV. The prognoses of patients with peritoneum-only metastasis were superior to those of patients with a stage IVB (P < 0.0001). Of the 11 independent prognostic factors identified, eight with a hazard ratio greater than 1.3 (depth of tumor invasion, regional lymph node metastasis, histologic grade, liver metastasis, lung metastasis, distant lymph node metastasis, peritoneal metastasis, and curative resection) were used in the prognostic scoring system. The scoring system gave one or two points for the presence of each prognosis risk factor, resulting in a total score ranging from 0 to 9. The 5-year overall survival rates of patients with a total score of 0-2, 3, 4, 5, and 6-9 were 50.4, 30.4, 17.7, 7.7, and 4.0 %, respectively (P < 0.0001).
CONCLUSION: Although the AJCC staging for patients with stage IV colorectal cancer reflected the prognosis, patients with peritoneum-only metastases should be classified as stage IVA. The prognostic scoring system using eight independent factors is useful in predicting the survival of patients with stage IV colorectal cancer.

Entities:  

Mesh:

Year:  2012        PMID: 22692571     DOI: 10.1007/s10147-012-0433-5

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  15 in total

1.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

2.  Changing management and survival in patients with stage IV colorectal cancer.

Authors:  Cameron Platell; Siobhan Ng; Austin O'bichere; Niall Tebbutt
Journal:  Dis Colon Rectum       Date:  2011-02       Impact factor: 4.585

3.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

Authors:  L B Saltz; J V Cox; C Blanke; L S Rosen; L Fehrenbacher; M J Moore; J A Maroun; S P Ackland; P K Locker; N Pirotta; G L Elfring; L L Miller
Journal:  N Engl J Med       Date:  2000-09-28       Impact factor: 91.245

4.  Colorectal cancer statistics in Japan: data from JSCCR registration, 1974-1993.

Authors:  T Muto; K Kotake; Y Koyama
Journal:  Int J Clin Oncol       Date:  2001-08       Impact factor: 3.402

5.  Validation and clinical use of the Japanese classification of colorectal carcinomatosis: benefit of surgical cytoreduction even without hyperthermic intraperitoneal chemotherapy.

Authors:  Hirotoshi Kobayashi; Masayuki Enomoto; Tetsuro Higuchi; Hiroyuki Uetake; Satoru Iida; Toshiaki Ishikawa; Megumi Ishiguro; Kenichi Sugihara
Journal:  Dig Surg       Date:  2010-11-10       Impact factor: 2.588

6.  FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.

Authors:  Christophe Tournigand; Thierry André; Emmanuel Achille; Gérard Lledo; Michel Flesh; Dominique Mery-Mignard; Emmanuel Quinaux; Corinne Couteau; Marc Buyse; Gérard Ganem; Bruno Landi; Philippe Colin; Christophe Louvet; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2003-12-02       Impact factor: 44.544

7.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

8.  Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.

Authors:  Carsten Bokemeyer; Igor Bondarenko; Anatoly Makhson; Joerg T Hartmann; Jorge Aparicio; Filippo de Braud; Serban Donea; Heinz Ludwig; Gunter Schuch; Christopher Stroh; Anja H Loos; Angela Zubel; Piotr Koralewski
Journal:  J Clin Oncol       Date:  2008-12-29       Impact factor: 44.544

9.  Changes in colorectal cancer during a 20-year period: an extended report from the multi-institutional registry of large bowel cancer, Japan.

Authors:  Kenjiro Kotake; Satoshi Honjo; Kenichi Sugihara; Tomoyuki Kato; Susumu Kodaira; Takashi Takahashi; Masayuki Yasutomi; Tetsuichiro Muto; Yasuo Koyama
Journal:  Dis Colon Rectum       Date:  2003-10       Impact factor: 4.585

10.  Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

Authors:  Eric Van Cutsem; Claus-Henning Köhne; Erika Hitre; Jerzy Zaluski; Chung-Rong Chang Chien; Anatoly Makhson; Geert D'Haens; Tamás Pintér; Robert Lim; György Bodoky; Jae Kyung Roh; Gunnar Folprecht; Paul Ruff; Christopher Stroh; Sabine Tejpar; Michael Schlichting; Johannes Nippgen; Philippe Rougier
Journal:  N Engl J Med       Date:  2009-04-02       Impact factor: 91.245

View more
  14 in total

1.  Pulmonary metastasis in newly diagnosed colon-rectal cancer: a population-based nomogram study.

Authors:  Yiwei Huang; Mengnan Zhao; Jiacheng Yin; Tao Lu; Xiaodong Yang; Guangda Yuan; Ming Li; Yu Liu; Cheng Zhan; Qun Wang
Journal:  Int J Colorectal Dis       Date:  2019-03-11       Impact factor: 2.571

2.  Significance of E-cadherin and CD44 expression in patients with unresectable metastatic colorectal cancer.

Authors:  Yasuhito Iseki; Masatsune Shibutani; Kiyoshi Maeda; Hisashi Nagahara; Tetsuro Ikeya; Kosei Hirakawa
Journal:  Oncol Lett       Date:  2017-05-26       Impact factor: 2.967

3.  Verifying the M1c category of CRC: analysis of the data from a Japanese multi-institutional database.

Authors:  Toshimichi Tanaka; Heita Ozawa; Yusuke Nakagawa; Akira Hirata; Shin Fujita; Kenichi Sugihara
Journal:  Int J Colorectal Dis       Date:  2019-12-03       Impact factor: 2.571

Review 4.  Personalizing prognosis in colorectal cancer: A systematic review of the quality and nature of clinical prognostic tools for survival outcomes.

Authors:  Alyson L Mahar; Carolyn Compton; Susan Halabi; Kenneth R Hess; Martin R Weiser; Patti A Groome
Journal:  J Surg Oncol       Date:  2017-08-02       Impact factor: 3.454

5.  Nomograms for colorectal cancer: A systematic review.

Authors:  Kazushige Kawai; Eiji Sunami; Hironori Yamaguchi; Soichiro Ishihara; Shinsuke Kazama; Hiroaki Nozawa; Keisuke Hata; Tomomichi Kiyomatsu; Junichiro Tanaka; Toshiaki Tanaka; Takeshi Nishikawa; Joji Kitayama; Toshiaki Watanabe
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

6.  A scoring model for predicting survival following primary tumour resection in stage IV colorectal cancer patients with unresectable metastasis.

Authors:  S R Dorajoo; W J H Tan; S X Koo; W S Tan; M H Chew; C L Tang; H L Wee; C W Yap
Journal:  Int J Colorectal Dis       Date:  2015-10-21       Impact factor: 2.571

7.  Impact of adjuvant chemotherapy in patients with curatively resected stage IV colorectal cancer.

Authors:  Hirotoshi Kobayashi; Kenjiro Kotake; Kenichi Sugihara
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

8.  SERPINI1 regulates epithelial-mesenchymal transition in an orthotopic implantation model of colorectal cancer.

Authors:  Yasufumi Matsuda; Koh Miura; Junko Yamane; Hiroshi Shima; Wataru Fujibuchi; Kazuyuki Ishida; Fumiyoshi Fujishima; Shinobu Ohnuma; Hiroyuki Sasaki; Munenori Nagao; Naoki Tanaka; Kennichi Satoh; Takeshi Naitoh; Michiaki Unno
Journal:  Cancer Sci       Date:  2016-03-28       Impact factor: 6.716

9.  Synchronous Resectable Metastatic Colorectal Cancer: Lymph Node Involvement Predicts Poor Outcome.

Authors:  Jianfei Fu; Mengjie Jiang; Yinuo Tan; Jiao Yang; Lunpo Wu; Lin Feng; Shu Zheng; Ying Yuan
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

10.  Prognostic impact of histological categorisation of epithelial-mesenchymal transition in colorectal cancer.

Authors:  H Ueno; E Shinto; Y Kajiwara; S Fukazawa; H Shimazaki; J Yamamoto; K Hase
Journal:  Br J Cancer       Date:  2014-09-23       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.